On Thursday, Johnson & Johnson (NYS: JNJ) announced that its Janssen Biotech and Janssen Biologics subsidiaries have submitted applications in the U.S. and Europe regarding the use of their Stelara psoriasis drug.

A supplemental Biologics License Application was submitted to the FDA and a Type II Variation was submitted to the European Medicines Agency.

The new usage will be for the treatment of adult patients with active psoriatic arthritis, a chronic, debilitating immune-mediated inflammatory disease affecting more than 2 million patients in the U.S., an estimated 4.2 million patients in Europe, and perhaps as many as 37 million people worldwide.

Johnson & Johnson noted that its twin applications are support by findings from a Phase 3 clinical trial. The company further noted that this same drug is currently in Phase 3 development for the treatment of moderately to severely active Crohn's disease.


The article Johnson & Johnson Seeks to Expand Use of Psoriasis Drug originally appeared on Fool.com.

Fool contributor Rich Smith has no positions in the stocks mentioned above. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services recommend Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Increase your money and finance knowledge from home

Reading a Stock Quote

Learn to read the ingredients of a stock.

View Course »

Introduction to Preferred Shares

Learn the difference between preferred and common shares.

View Course »

Add a Comment

*0 / 3000 Character Maximum